---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001553"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:39:27.814633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Q4 2024 IMCIVREE revenue $41.8M; cash runway extended to 2027

## Summary
- Q4 2024 IMCIVREE net revenue $41.8M (+26% sequential, +73% YoY); FY2024 total $130.1M.
- Net loss Q4 2024 ($44.6M) or ($0.72)/share vs ($41.6M) in Q4 2023; FY loss ($264.6M).
- Raised ~$75M gross proceeds from ATM (1.3M shares at ~$56.30); cash $320.6M at Dec 31, 2024.
- FDA and UK MHRA expanded IMCIVREE label to children as young as 2 years old.
- Phase 3 acquired hypothalamic obesity trial topline data expected Q2 2025.

## SEC filing metadata
- accession: 0001558370-25-001553
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/0001558370-25-001553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001553
- JSON: https://secwatch.observer/filing/0001558370-25-001553.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.